Why Patients Switch from Mounjaro to 1.7mg Wegovy
Making the Switch: 1.7mg Wegovy vs Mounjaro Cost Comparison
When comparing 1.7mg Wegovy vs Mounjaro, cost often drives the switching decision for many patients. EverydayMeds offers 1.7mg Wegovy at £139.99 per pen, representing significant monthly savings compared to private Mounjaro prescriptions which can exceed £200 monthly. Our Elevate Duo bundle (1.7mg & 2.4mg) at £369.99 provides a perfect transition package for patients moving toward maintenance dosing. This strategic pairing allows you to complete your current dose escalation whilst preparing for long-term treatment.
The financial advantage becomes even more pronounced when considering storage flexibility and travel convenience. Wegovy maintains its efficacy for up to 6 weeks at room temperature below 30°C, compared to Mounjaro's 21-day limit. For frequent travellers or those with unreliable refrigeration, this extended stability reduces medication waste and replacement costs, making the 1.7mg Wegovy vs Mounjaro comparison even more favourable from a practical standpoint.
Clinical Equivalence: 1.7mg Wegovy vs Mounjaro Mechanisms
Understanding the medication differences helps inform your 1.7mg Wegovy vs Mounjaro switching decision. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your natural fullness hormone, whilst Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors as a dual agonist. Both medications reduce appetite and promote satiety, though they achieve this through slightly different pathways. Your prescriber can determine equivalent dosing when transitioning between treatments.
Clinical evidence supports both medications' effectiveness, with Wegovy demonstrating approximately 15% average weight loss in the STEP trials (Wilding et al., NEJM, 2021). The 1.7mg dose represents week 13-16 of treatment, where patients typically experience accelerated results as they approach maintenance therapy. Most patients find the switching process straightforward when guided by experienced prescribers who understand the nuances of 1.7mg Wegovy vs Mounjaro dosing equivalence.
STEP Trial Evidence for 1.7mg Wegovy Effectiveness
The robust clinical evidence supporting Wegovy comes from the comprehensive STEP trial programme, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). Patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved sustained weight management throughout the study period. The 1.7mg dose sits within the escalation phase where patients typically begin experiencing the medication's full appetite suppression benefits.
Additional studies including STEP 2 showed approximately clinically studied weight loss in patients with type 2 diabetes, whilst STEP 5 demonstrated 15.2% sustained weight loss at 2 years. When considering 1.7mg Wegovy vs Mounjaro, both medications have demonstrated clinical efficacy, though direct head-to-head trials remain limited due to different trial designs and patient populations.
How Wegovy's GLP-1 Mechanism Supports Weight Management
Wegovy's semaglutide works by mimicking GLP-1, a natural hormone released when you eat that signals fullness to your brain. This prescription-only medicine binds to GLP-1 receptors in appetite centres, reducing hunger signals and promoting satiety after smaller meals. Unlike simple appetite suppressants, Wegovy works with your body's natural regulatory systems to support sustainable weight management. The medication also slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged feelings of fullness. Most patients report reduced food cravings and easier portion control, making it easier to maintain the reduced-calorie diet essential for optimal results.
Seamless Ordering Process for 1.7mg Wegovy
Switching to 1.7mg Wegovy through EverydayMeds involves a streamlined 3-minute online clinical assessment covering your medical history, current medications, and treatment goals. Our qualified prescribers review your assessment within 3 working days (or 24 hours with express service), considering your previous Mounjaro experience and any switching requirements. Once approved, your 1.7mg Wegovy ships via next-day delivery in cold-chain, temperature-controlled packaging to ensure medication integrity. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access our best pricing. Our GPhC-registered pharmacy (#9012878) ensures all medications meet UK quality standards throughout the switching process.
Storage Advantages and Practical Considerations
The 1.7mg Wegovy vs Mounjaro comparison reveals significant practical advantages for Wegovy users. Store your FlexTouch pen in the fridge at 2-8°C before first use, but once removed, it remains stable for up to 6 weeks at room temperature below 30°C. This extended stability surpasses Mounjaro's 21-day room temperature limit, making Wegovy ideal for travel, work schedules, or emergency situations. Each pen delivers four weeks of once-weekly injections, with dose escalation following a specific schedule from 0.25mg through 2.4mg maintenance. The FlexTouch design offers precise, comfortable injections with minimal preparation required. Most patients find the weekly routine convenient compared to daily medications, supporting better adherence throughout their weight management journey.
Switching Safely: 1.7mg Wegovy vs Mounjaro Transition Guide
Patients considering the 1.7mg Wegovy vs Mounjaro switch should work closely with prescribers to ensure safe transition protocols. Most switches involve stopping your current medication and beginning Wegovy at an appropriate dose based on your previous treatment duration and tolerance. Some patients may need to start at a lower Wegovy dose initially, even if previously tolerating higher Mounjaro doses, due to different receptor mechanisms and pharmacokinetics.
Common switching reasons include cost optimization, side effect management, storage convenience, or personal preference for once-weekly semaglutide over dual-agonist therapy. EverydayMeds stocks both medications, eliminating pharmacy changes during your transition and ensuring consistent supply throughout the switching process. Our prescribers understand 1.7mg Wegovy vs Mounjaro equivalencies and can customize your switching timeline based on individual factors.
Maximize Your Savings with Strategic Bundle Planning
Beyond the immediate 1.7mg Wegovy vs Mounjaro cost savings, strategic bundle selection maximizes your long-term value. Our Elevate Duo combines 1.7mg and 2.4mg pens for £369.99, perfect for patients transitioning to maintenance therapy. Returning customers benefit from the DOSE25 code to maintain optimal pricing across multiple orders. Consider our Consistency 1.7mg bundle (two 1.7mg pens) at £309.99 if your prescriber recommends extending this dose phase before advancing to maintenance. Planning ahead reduces ordering frequency whilst ensuring uninterrupted treatment during your weight management journey. With both Wegovy and Mounjaro available from EverydayMeds, your prescriber can help determine which option best suits your clinical needs and financial goals. Contact our clinical team for personalized switching guidance and bundle recommendations.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
